# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jim Thorpe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML011-SYN
- Date: 2026-07-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nolan Fairbanks, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two weeks after excision of the lip cancer: pathology, wound check, surveillance plan, lipids, and cardiac rehabilitation. **S**

## History of present illness

Mr. Thorpe returns two weeks after V-excision of the lower lip cancer by Dr. Ferrante. The CT of the neck before surgery showed no enlarged or abnormal lymph nodes. He took acetaminophen for three days after the operation and needed nothing stronger. The stitches were removed last week. His lip feels a little tight but he can whistle, drink from a cup and speak clearly. He has had no chest tightness since the first week of his medicines and has not used nitroglycerin. He took aspirin throughout and had only slight oozing on the first night. He is keen to start cardiac rehabilitation. **S**

| Element | Detail |
|---|---|
| Surgery | V-excision two weeks ago; stitches out; lip function normal |
| Neck CT before surgery | No enlarged or abnormal lymph nodes |
| Angina | None for four weeks |
| Medicines | Aspirin, atorvastatin 80 mg and metoprolol taken daily |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Ears, nose, mouth, and throat | Positive | Lip slightly tight; no pain, drooling, or trouble eating |
| Cardiovascular | Negative | No chest tightness, palpitations, or leg swelling |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Neurological | Negative | Lip sensation normal |

4 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue for chest pain, repeated every 5 minutes up to 3 tablets **S**
- Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/78 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 93 kg; BMI 27.2 kg/m². All vital signs are synthetic.

Total cholesterol: 136 mg/dL; LDL cholesterol: 68 mg/dL; HDL cholesterol: 42 mg/dL; Triglycerides: 130 mg/dL; ALT: 31 U/L. All results are synthetic.

## Change since baseline

- Total cholesterol: 238 mg/dL (high) at baseline, 136 mg/dL at this visit **S**
- LDL cholesterol: 158 mg/dL (high) at baseline, 68 mg/dL at this visit **S**
- HDL cholesterol: 38 mg/dL (low) at baseline, 42 mg/dL at this visit **S**
- Triglycerides: 210 mg/dL (high) at baseline, 130 mg/dL at this visit **S**
- ALT: 24 U/L at baseline, 31 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 128/78, pulse 62; weight 93.0 kg |
| Head and neck | Lower lip scar healing well, vermilion line aligned; good lip closure; no nodularity; mouth normal; no neck nodes |
| Cardiovascular | Regular rhythm; no murmur |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Squamous cell carcinoma of the left lower lip, excised** (C00.1). Pathology: invasive keratinizing squamous cell carcinoma, well differentiated, 1.3 cm, depth of invasion 2.5 mm, no perineural or lymphovascular invasion, all margins clear (closest, deep, 6 mm). With a clinically and radiologically negative neck, this is pathologic T1, clinical N0, stage I. No further treatment is needed; the neck is observed because the depth of invasion is small. Surveillance follows the NCCN schedule. **S**
   - Lip, mouth and neck examination every 1 to 3 months for the first year.
   - Lip balm with sunscreen and a hat; skin checks.
   - Dental check-up.
2. **Chronic coronary disease with stable angina** (I25.119). No angina for four weeks; blood pressure 128/78. LDL 68 mg/dL from 158, a 57% fall on atorvastatin 80 mg, but above the secondary-prevention goal of 55 mg/dL. ALT 31 U/L; no muscle symptoms. **S**
   - Add ezetimibe 10 mg daily.
   - Lipid panel in 8 to 10 weeks.
   - Begin cardiac rehabilitation, three sessions a week.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Examination of the lips, mouth, and neck | Every 1 to 3 months in year 1, 2 to 6 months in year 2, 4 to 8 months in years 3 to 5, then yearly | Completed today | Scar healing; no nodularity; no neck nodes |
| Laboratory | Pathology: type, margins, depth of invasion, perineural and lymphovascular invasion | Full pathology after excision | Completed today | pT1, depth of invasion 2.5 mm, margins clear (closest 6 mm), no perineural or lymphovascular invasion |
| Imaging | Imaging of the primary site and neck | Before treatment as indicated; afterwards only for symptoms or findings | Up to date | Neck CT before surgery: no abnormal nodes; no routine imaging afterwards |
| Laboratory | TSH | Every 6 to 12 months only if the neck was irradiated | Not indicated | Neck not irradiated |
| Self-management | Sun protection of the lips and skin | Every visit | Completed today | Using lip balm with sunscreen and a hat |
| Self-management | Tobacco and alcohol use | Every visit | Completed today | Tobacco-free; alcohol one or two beers some weekends |
| Referral | Dental evaluation | After diagnosis, then routine | Due | Dental check-up advised; he will look into options |
| Examination | Blood pressure (goal below 130/80) | Every visit | Completed today | 128/78 |
| Examination | Weight, BMI, and physical activity | Every visit | Completed today | 93.0 kg, BMI 27.2 |
| Survey | Angina frequency and nitroglycerin use | Every visit | Completed today | None for four weeks; no nitroglycerin |
| Medication safety | Adherence and side effects: aspirin, high-intensity statin, beta-blocker | Every visit | Completed today | All taken daily; no muscle symptoms |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing lipid therapy, then every 3 to 12 months; goal LDL below 55 mg/dL | Completed today | Five weeks after starting atorvastatin: total cholesterol 136, LDL 68, HDL 42, triglycerides 130 mg/dL; ezetimibe added |
| Laboratory | ALT on statin | Baseline; repeat only for symptoms | Completed today | 31 U/L |
| Referral | Cardiac rehabilitation | After a heart attack or for stable angina: up to 36 sessions | Referred | Starting this month, three sessions a week |

## Goal progress

- Lip cancer removed with clear margins and no recurrence on surveillance through four months. In progress; target 2026-10-26. **S**
- LDL cholesterol below 55 mg/dL on secondary prevention. In progress; target 2026-09-21. **S**
- Blood pressure below 130/80 mmHg. In progress; target 2026-09-21. **S**
- Complete cardiac rehabilitation and walk uphill without angina. In progress; target 2026-10-26. **S**
- Stay tobacco-free and protect his lips and skin from the sun. In progress; target 2026-10-26. **S**

## Medication changes

- Started: Ezetimibe 10 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers (cancer of the lip and oral cavity) (2026), National Comprehensive Cancer Network
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation)
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol (2018), American Heart Association and American College of Cardiology (Circulation)
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease monograph (2026), Aether Forge

## Follow-up

- Cardiac rehabilitation three times a week. Visit in about ten weeks with a lipid panel and lip examination. **S**
- Next scheduled visit 2026-09-21: coronary disease review in cardiac rehabilitation, lipid recheck after ezetimibe, and lip surveillance. **S**
